RxDoctor Payments Data

Erin Sinnaeve, APRN

Nurse Practitioner · Aurora, ILNPI 1649432287

Payments from drug & device makers

$1,486in general payments, 2019–2025

Across 52 payments — averaging $28.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$477
  • Regeneron Healthcare Solutions, Inc.$316
  • Sanofi$246
  • Amgen$202
  • AstraZeneca$202
  • Aimmune Therapeutics, Inc.$28
  • plus $15 from 1 others

What the payments were for

  • Food & beverage$1,37192%
  • Education$1158%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,486 in reported general payments places this provider in the 85th percentile of 4,869 nurse practitioner providers in Illinois.

See all nurse practitioner providers in Illinois

Medicare billing

Part B allowed, 2024
$21,347
Medicare patients
82
Services billed
1,563

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab22$80,537
XolairOmalizumab21$61,016
Trelegy ElliptaFluticasone/Umeclidin/Vilanter39$39,511
Breo ElliptaFluticasone/Vilanterol40$17,556
Advair HfaFluticasone Propion/Salmeterol18$10,075
Combivent RespimatIpratropium/Albuterol Sulfate14$6,804
Qvar RedihalerBeclomethasone Dipropionate13$4,113
Fluticasone-SalmeterolFluticasone Propion/Salmeterol16$3,277
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate14$2,579
Albuterol Sulfate HfaAlbuterol Sulfate37$1,331
Ipratropium Bromide67$1,159
Azelastine Hcl41$1,119
Montelukast Sodium52$773
Fluticasone Propionate35$622
Famotidine26$307

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$477$57,06779 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,869 nurse practitioner providers in Illinois.

Other nurse practitioner in Aurora

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →